

PRODUCT INFORMATION



[Asp³⁷¹]-Tyrosinase (369-377) (human) (trifluoroacetate salt)

Item No. 40152

Formal Name: (2S,5S,8S,11S,14S,20S)-20-((S)-2-((S)-2-amino-3-(4-hydroxyphenyl)propanamido)-4-(methylthio)butanamido)-5-(3-amino-3-oxopropyl)-14-((R)-1-hydroxyethyl)-8-(hydroxymethyl)-2-isopropyl-11-(2-(methylthio)ethyl)-4,7,10,13,16,19-hexaamino-3,6,9,12,15,18-hexaazadocosanedioic acid, trifluoroacetate salt

Synonyms: [Asp³⁷⁰]-Tyrosinase (368-376), Tyr-Met-Asp-Gly-Thr-Met-Ser-Gln-Val

Peptide Sequence: YMDGTMSQV-OH

MF: C₄₂H₆₆N₁₀O₁₆S₂ • XCF₃COOH


FW: 1,031.2

Purity: ≥98% (mixture of isomers)

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

[Asp³⁷¹]-Tyrosinase (369-377) (human) (trifluoroacetate salt) is supplied as a solid. A stock solution may be made by dissolving the [Asp³⁷¹]-Tyrosinase (369-377) (human) (trifluoroacetate salt) in water. We do not recommend storing the aqueous solution for more than one day.

Description

[Asp³⁷¹]-Tyrosinase (369-377) is a naturally occurring tyrosinase antigen peptide.¹ It is formed *via* post-translational modification of Asn371.² [Asp³⁷¹]-Tyrosinase (369-377) binds to MHC class I subtype HLA-A*0201-positive T2 cells (IC₅₀ = 1.2 µg/ml) and induces lysis of HLA-A2.1-positive T2 cells incubated with cytotoxic T lymphocytes in a concentration-dependent manner.^{3,4} Immunization with [Asp³⁷¹]-tyrosinase (369-377)-pulsed, CD40L-activated autologous dendritic cells delays tumor growth in an AAD-expressing B16-F1 melanoma model using transgenic mice expressing HLA-A*0201 linked to the CD8-binding domain of H-2D^d (AAD){69706}

References

1. Skipper, J.C.H., R.C., Gulden, P.H., Brichard, V., *et al. J. Exp. Med.* **83**(2), 527-534 (1996).
2. Mosse, C.A., Meadows, L., Luckey, C.J., *et al. J. Exp. Med.* **87**(1), 37-48 (1998).
3. van Elsas, A., van der Burg, S.H., van der Minne, C.E., *et al. Eur. J. Immunol.* **26**(8), 1683-1689 (1996).
4. Mullis, D.W., Bullock, T.N.J., Colella, T.A., *et al. J. Immunol.* **67**(9), 4853-4860 (2001).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/04/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM